Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor

Thrombosis and Haemostasis

Volumn 108, Issue 6, 2012, Pages 1180-1191

  Chan, Mark Y ^a   Lin, Min ^b   Lucas, Joseph ^c   Moseley, Arthur ^c   Will Thompson, J ^c   Cyr, Derek ^c   Ueda, Hitoshi ^d   Kajikawa, Mariko ^d   Ortel, Thomas L ^e   Becker, Richard C ^e,f  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

^d BAYER YAKUHIN LTD   (Japan)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Atrial fibrillation; Proteomics; Thrombomodulin; Warfarin and factor Xa inhibitor

Indexed keywords

APOLIPOPROTEIN C2; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 13A; BLOOD CLOTTING FACTOR 13B; COMPLEMENT COMPONENT C5; FIBULIN; GELATINASE B; HEMOGLOBIN ALPHA CHAIN; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 8; PLASMA PROTEIN; RIVAROXABAN; STROMELYSIN; THROMBOMODULIN; VITRONECTIN; WARFARIN;

AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; BLOOD PROTEINS; FACTOR XA; FEMALE; HEMORRHAGE; HUMANS; MALE; MORPHOLINES; PROTEOMICS; RISK FACTORS; STROKE; THIOPHENES; THROMBOSIS; WARFARIN;

EID: 84871443198     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-05-0310     Document Type: Article

References (23)

1. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009; 373: 155-166.
2. Hertervig EJ, Yuan S, Carlson J, et al. Evidence for electrical remodelling of the atrial myocardium in patients with atrial fibrillation. A study using the monophasic action potential recording technique. Clin Physiol Funct Imaging 2002; 22: 8-12.
3. Polyakova V, Miyagawa S, Szalay Z, et al. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 2008; 12: 189-208.
4. Mayr M, Yusuf S, Weir G, et al. Combined metabolomic and proteomic analysis of human atrial fibrillation. J Am Coll Cardiol 2008; 51: 585-594.
5. Tchabo NE, Liel MS, Kohn EC. Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer. Am J Pharmacogenomics 2005; 5: 141-148.
6. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 2007; 9: 1006-1023.
7. Kamath S, Blann AD, Chin BS, et al. A prospective randomized trial of aspirinclopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 2002; 40: 484-490.
8. Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000; 31: 828-833.
9. Lucas JE, Kung HN, Chi JT. Latent factor analysis to discover pathway-associated putative segmental aneuploidies in human cancers. PLoS Comput Biol 2010; 6: e1000920.
10. Lip GY. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med 2011; 124: 111-114.
11. Loscalzo J. Personalized cardiovascular medicine and drug development: time for a new paradigm. Circulation 2012; 125: 638-645.
12. Tu C, Rudnick PA, Martinez MY, et al. Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res 2010; 9: 4982-4991.
13. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005; 563: 23-60.
14. Ohlin AK, Larsson K, Hansson M. Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma. J Thromb Haemost 2005; 3: 976-982.
15. Ito T, Maruyama I. Thrombomodulin: Protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 2011; 9 (Suppl 1): 168-173.
16. Lind M, Boman K, Johansson L, et al. Thrombomodulin as a marker for bleeding complications during warfarin treatment. Arch Intern Med 2009; 169: 1210-1215.
17. Yamashita T, Sekiguchi A, Iwasaki YK, et al. Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation 2003; 108: 2450-2452.
18. Freestone B, Chong AY, Nuttall S, et al. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest 2007; 132: 1253-1258.
19. Li-Saw-Hee FL, Blann AD, Goldsmith I, et al. Indexes of hypercoagulability measured in peripheral blood reflect levels in intracardiac blood in patients with atrial fibrillation secondary to mitral stenosis. Am J Cardiol 1999; 83: 1206-1209.
20. Raife TJ, Dwyre DM, Stevens JW, et al. Human thrombomodulin knock-in mice reveal differential effects of human thrombomodulin on thrombosis and atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31: 2509-2517.
21. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 2006; 368: 33-47.
22. Gramley F, Lorenzen J, Plisiene J, et al. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol 2007; 18: 1076-1082.
23. Brundel BJ, Shiroshita-Takeshita A, Qi X, et al. Induction of heat shock response protects the heart against atrial fibrillation. Circ Res 2006; 99: 1394-1402.